Approaches to palliative therapies for Alzheimer's disease.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Current Topics in Medicinal Chemistry

• Publication date

  2006-02-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/156802606776743039PMID 16712491
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Disease modifying strategies for the treatment of Alzheimer's disease targeted at modulating levels of the beta-amyloid peptide.

  2005cited by this paper
• The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats.

  2005cited by this paper
• Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.

  2005cited by this paper
• Muscarinic receptor agonists and antagonists in the treatment of Alzheimer's disease.

  2005cited by this paper
• Interaction of chiral MS-245 analogs at h5-HT6 receptors.

  2005cited by this paper
• Therapeutic opportunities in Alzheimer disease: one for all or all for one?

  2005cited by this paper
• Progress in the discovery of BACE inhibitors.

  2005cited by this paper
• Long-lasting cognitive improvement with nicotinic receptor agonists: mechanisms of pharmacokinetic-pharmacodynamic discordance.

  2005cited by this paper
• Bicyclic heteroarylpiperazines as selective brain penetrant 5-HT6 receptor antagonists.

  2005cited by this paper
• Role of endogenous cannabinoids in cognition and emotionality.

  2005cited by this paper
• Synthesis and biological evaluation of benzodioxanylpiperazine derivatives as potent serotonin 5-HT(1A) antagonists: the discovery of Lecozotan.

  2005cited by this paper
• Discovery and structure-activity relationship of quinuclidine benzamides as agonists of alpha7 nicotinic acetylcholine receptors.

  2005cited by this paper
• Gamma-secretase as a therapeutic target for the treatment of Alzheimer's disease.

  2005cited by this paper
• Discovery of 5-arylsulfonamido-3-(pyrrolidin-2-ylmethyl)-1H-indole derivatives as potent, selective 5-HT6 receptor agonists and antagonists.

  2005cited by this paper
• Keynote review: phosphodiesterase-4 as a therapeutic target.

  2005cited by this paper
• Discovery of the alpha7 nicotinic acetylcholine receptor agonists. (R)-3'-(5-Chlorothiophen-2-yl)spiro-1-azabicyclo[2.2.2]octane-3,5'-[1',3']oxazolidin-2'-one as a novel, potent, selective, and orally bioavailable ligand.

  2005cited by this paper
• Prevention of Alzheimer's Disease Pathology by Cannabinoids: Neuroprotection Mediated by Blockade of Microglial Activation

  2005cited by this paper
• 2-(Arylmethyl)-3-substituted quinuclidines as selective alpha 7 nicotinic receptor ligands.

  2005cited by this paper
• A Novel Positive Allosteric Modulator of the α7 Neuronal Nicotinic Acetylcholine Receptor: In Vitro and In Vivo Characterization

  2005cited by this paper
• N1-arylsulfonyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-indole derivatives are potent and selective 5-HT6 receptor antagonists.

  2005cited by this paper
• Conformationally constrained N1-arylsulfonyltryptamine derivatives as 5-HT6 receptor antagonists.

  2005cited by this paper
• Phosphodiesterase inhibitors for cognitive enhancement.

  2005cited by this paper
• Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.

  2005cited by this paper
• Synaptic targeting by Alzheimer's-related amyloid beta oligomers.

  2004cited by this paper
• Chemical genomics: massively parallel technologies for rapid lead identification and target validation

  2004cited by this paper
• Alzheimer Disease: Mechanistic Understanding Predicts Novel Therapies

  2004cited by this paper
• (+)-3-[2-(Benzo[b]thiophen-2-yl)-2-oxoethyl]-1-azabicyclo[2.2.2]octane as potent agonists for the alpha7 nicotinic acetylcholine receptor.

  2004cited by this paper
• Medicinal chemistry and biological properties of non-imidazole histamine H3 antagonists.

  2004cited by this paper
• Muscarinic M2 antagonists: anthranilamide derivatives with exceptional selectivity and in vivo activity.

  2004cited by this paper
• 1-alkyl-4-acylpiperazines as a new class of imidazole-free histamine H(3) receptor antagonists.

  2004cited by this paper
• Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system.

  2004cited by this paper
• Future directions in the treatment of Alzheimer’s disease

  2004cited by this paper
• Strategies for disease modification in Alzheimer's disease

  2004cited by this paper
• Role of the endocannabinoid system in Alzheimer's disease: new perspectives.

  2004cited by this paper
• Structure-activity relationships of A-331440: a new histamine-3 antagonist with anti-obesity properties

  2004cited by this paper
• 5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation--an effect sensitive to NMDA receptor antagonism.

  2004cited by this paper
• A new class of potent non-imidazole H(3) antagonists: 2-aminoethylbenzofurans.

  2004cited by this paper
• Targets of antidementive therapy: drugs with a specific pharmacological mechanism of action.

  2004cited by this paper
• Development of a presynaptic 5-HT1A antagonist.

  2003cited by this paper
• Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics.

  2003cited by this paper
• Two Novel and Selective Nonimidazole Histamine H3 Receptor Antagonists A-304121 and A-317920: I. In Vitro Pharmacological Effects

  2003cited by this paper
• Alzheimer disease in the US population: prevalence estimates using the 2000 census.

  2003cited by this paper
• The Glutamatergic System and Alzheimer’s Disease

  2003cited by this paper
• Systemic, but not local, administration of cannabinoid CB1 receptor agonists modulate prefrontal cortical acetylcholine efflux in the rat

  2003cited by this paper
• Effect of the 5-HT6 receptor antagonists Ro04-6790 and Ro65-7199 on latent inhibition and prepulse inhibition in the rat: comparison to clozapine.

  2003cited by this paper
• Bisquaternary dimers of strychnine and brucine. A new class of potent enhancers of antagonist binding to muscarinic M2 receptors.

  2003cited by this paper
• Orally efficacious NR2B-selective NMDA receptor antagonists.

  2003cited by this paper
• 1-Benzyloxy-4,5-dihydro-1H-imidazol-2-yl-amines, a novel class of NR1/2B subtype selective NMDA receptor antagonists.

  2003cited by this paper
• Systematic development of high affinity bis(ammonio)alkane-type allosteric enhancers of muscarinic ligand binding.

  2003cited by this paper
• Indole-2-carboxamides as novel NR2B selective NMDA receptor antagonists.

  2003cited by this paper
• An Assessment of the Effects of Serotonin 6 (5-HT6) Receptor Antagonists in Rodent Models of Learning

  2003cited by this paper
• The role of histamine and the tuberomamillary nucleus in the nervous system

  2003cited by this paper
• 4-(3,4-dihydro-1H-isoquinolin-2yl)-pyridines and 4-(3,4-dihydro-1H-isoquinolin-2-yl)-quinolines as potent NR1/2B subtype selective NMDA receptor antagonists.

  2003cited by this paper
• Synthetic studies on himbacine, a potent antagonist of the muscarinic M2 subtype receptor. Part 2: synthesis and muscarinic M2 subtype antagonistic activity of the novel himbacine congeners modified at the C-3 position of lactone moiety.

  2003cited by this paper
• Discovery of an ectopic activation site on the M(1) muscarinic receptor.

  2002cited by this paper
• The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics

  2002cited by this paper
• Alzheimer's Disease Is a Synaptic Failure

  2002cited by this paper
• The potential utility of 5-HT1A receptor antagonists in the treatment of cognitive dysfunction associated with Alzheimer s disease.

  2002cited by this paper
• International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors

  2002cited by this paper
• New drugs for Alzheimer's disease and other dementias

  2002cited by this paper
• Coordination of Histamine H3 Receptor Antagonists with Human Adrenal Cytochrome P450 Enzymes

  2002cited by this paper
• Histamine H3‐receptor‐mediated [35S]GTPγ[S] binding: evidence for constitutive activity of the recombinant and native rat and human H3 receptors

  2002cited by this paper
• Molecular, pharmacological and functional diversity of 5-HT receptors.

  2002cited by this paper
• Pharmacological profile of SB-357134: a potent, selective, brain penetrant, and orally active 5-HT(6) receptor antagonist.

  2002cited by this paper
• Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications.

  2001cited by this paper
• The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus.

  2001cited by this paper
• Alzheimer's disease: genes, proteins, and therapy.

  2001cited by this paper
• 5-HT6 receptor antagonists enhance retention of a water maze task in the rat

  2001cited by this paper
• Novel (4-piperazin-1-ylquinolin-6-yl) arylsulfonamides with high affinity and selectivity for the 5-HT(6) receptor.

  2001cited by this paper
• Identification of rat H3 receptor isoforms with different brain expression and signaling properties.

  2001cited by this paper
• Nicotinic receptor subtypes in human brain related to aging and dementia.

  2001cited by this paper
• The next generation of PDE4 inhibitors.

  2001cited by this paper
• The preclinical pharmacological profile of WAY-132983, a potent M1 preferring agonist.

  2000cited by this paper
• Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells.

  2000cited by this paper
• High constitutive activity of native H3 receptors regulates histamine neurons in brain

  2000cited by this paper
• Syntheses of R and S isomers of AF-DX 384, a selective antagonist of muscarinic M2 receptors.

  2000cited by this paper
• (-)-Spiro[1-azabicyclo[2.2.2]octane-3,5'-oxazolidin-2'-one], a conformationally restricted analogue of acetylcholine, is a highly selective full agonist at the alpha 7 nicotinic acetylcholine receptor.

  2000cited by this paper
• N1-(Benzenesulfonyl)tryptamines as novel 5-HT6 antagonists.

  2000cited by this paper
• In vivo effects of the 5‐HT6 antagonist SB‐271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5‐HT, glutamate and aspartate

  2000cited by this paper
• Cognitive and behavioral heterogeneity in Alzheimer's disease: seeking the neurobiological basis.

  2000cited by this paper
• The novel 5-Hydroxytryptamine(1A) antagonist LY426965: effects on nicotine withdrawal and interactions with fluoxetine.

  2000cited by this paper
• 5-Chloro-N-(4-methoxy-3-piperazin-1-yl- phenyl)-3-methyl-2-benzothiophenesulfon- amide (SB-271046): a potent, selective, and orally bioavailable 5-HT6 receptor antagonist.

  1999cited by this paper
• Cholinesterase Inhibitors: A Therapeutic Strategy for Alzheimer Disease

  1999cited by this paper
• Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn.

  1999cited by this paper
• Antibodies and Antisense Oligonucleotide for Probing the Distribution and Putative Functions of Central 5-HT6Receptors

  1999cited by this paper
• A review of central 5-HT receptors and their function.

  1999cited by this paper
• Natural history of behavioural changes and psychiatric symptoms in Alzheimer's disease

  1999cited by this paper
• 2-Fluoro-4-pyridinylmethyl analogues of linopirdine as orally active acetylcholine release-enhancing agents with good efficacy and duration of action.

  1998cited by this paper
• Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist.

  1998cited by this paper
• Characterization of Ro 04‐6790 and Ro 63‐0563: potent and selective antagonists at human and rat 5‐HT6 receptors

  1998cited by this paper
• The pharmacological characterization of a novel selective 5-hydroxytryptamine1A receptor antagonist, NAD-299.

  1997cited by this paper
• Ro 25-6981, a highly potent and selective blocker of N-methyl-D-aspartate receptors containing the NR2B subunit. Characterization in vitro.

  1997cited by this paper
• Cholinergic activity and amyloid precursor protein metabolism.

  1997cited by this paper
• Potential Role of Muscarinic Agonists in Alzheimer’s Disease

  1997cited by this paper
• Cloning, Characterization, and Chromosomal Localization of a Human 5‐HT6 Serotonin Receptor

  1996cited by this paper
• A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635.

  1995cited by this paper
• Emetic, central nervous system, and pulmonary activities of rolipram in the dog.

  1995cited by this paper
• Facilitation of acetylcholine release and cognitive performance by an M(2)-muscarinic receptor antagonist in aged memory-impaired

  1995cited by this paper
• Effects of altered 5-ht6 expression in the rat: functional studies using antisense oligonucleotides.

  1995cited by this paper
• Determination of the role of the 5-ht6 receptor in the rat brain: a study using antisense oligonucleotides.

  1995cited by this paper

• Inhibition of Acetylcholinesterase by Novel Lupinine Derivatives

  2023cites this paper
• The Role of Nanomedicine in the Treatment of Neurodegenerative Disorders

  2019cites this paper
• Centella asiatica, an Ayurvedic Medicinal Plant, Prevents the Major Neurodegenerative and Neurotoxic Mechanisms Associated with Cognitive Impairment

  2017cites this paper
• Thiosemicarbazone Moiety Assist in Interaction of Planar Aromatic Molecules with Amyloid Beta Peptide and Acetylcholinesterase

  2017cites this paper
• Ru(II)‐p‐cymene Thiosemicarbazone Complexes as Inhibitors of Amyloid β (Aβ) Peptide Aggregation and Aβ‐Induced Cytotoxicity

  2017cites this paper
• In vitro anti-neuroinflammatory and neuritogenic stimulatory effects of a medicinal mushroom lignosus rhinocerotis (Cooke) ryvarden / Syntyche Seow Ling Sing

  2016cites this paper
• (-)-Meptazinol-melatonin hybrids as novel dual inhibitors of cholinesterases and amyloid-β aggregation with high antioxidant potency for Alzheimer's therapy.

  2015cites this paper
• Nanomedicine for Neurological Disorder

  2014cites this paper
• Molecular Mechanisms of Neuroprotection and Cognitive Enhancement by an Alternative drug Centella asiatica

  2013cites this paper
• Restoring long-term potentiation impaired by amyloid-beta oligomers: comparison of an acetylcholinesterase inhibitior and selective neuronal nicotinic receptor agonists.

  2013cites this paper
• Hologram QSAR Models of 4-[(Diethylamino)methyl]-phenol Inhibitors of Acetyl/Butyrylcholinesterase Enzymes as Potential Anti-Alzheimer Agents

  2012cites this paper
• Polymeric nanocarriers and nanoreactors: a survey of possible therapeutic applications.

  2012cites this paper
• Preventive effect of piracetam and vinpocetine on hypoxia-reoxygenation induced injury in primary hippocampal culture.

  2011cites this paper
• 5-HT6 medicinal chemistry.

  2010cites this paper
• Cell based-gene delivery approaches for the treatment of spinal cord injury and neurodegenerative disorders.

  2010cites this paper
• An enzyme-linked immunosorbent assay to compare the affinity of chemical compounds for β-amyloid peptide as a monomer

  2010cites this paper
• Macrocyclic BACE inhibitors: Optimization of a micromolar hit to nanomolar leads.

  2010cites this paper
• Approaches to Amyloid Therapies for the Treatment of Alzheimer's Disease

  2010cites this paper
• Progress toward the development of a viable BACE‐1 inhibitor

  2009cites this paper
• Identification of a series of benzoxazoles as potent 5-HT6 ligands.

  2009cites this paper
• 5‐HT6 antagonists as potential treatment for cognitive dysfunction

  2009influential citation
• 1-Sulfonylindazoles as potent and selective 5-HT6 ligands.

  2009cites this paper
• Neurodegenerative disorders and nanoformulated drug development.

  2009cites this paper
• Dendrimer-epidermal growth factor conjugate displays superagonist activity.

  2008cites this paper
• 1,2,5-THIADIAZOLES

  2008cites this paper
• 2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (beta-site APP cleaving enzyme): Use of structure based design to convert a micromolar hit into a nanomolar lead.

  2007cites this paper
• Nanomedicine in the diagnosis and therapy of neurodegenerative disorders.

  2007cites this paper
• Study on dual-site inhibitors of acetylcholinesterase: Highly potent derivatives of bis- and bifunctional huperzine B.

  2007cites this paper
• Beyond amyloid: the next generation of Alzheimer's disease therapeutics.

  2007cites this paper
• Complete resolution of the microscopic protonation equilibria of N-methyl-D-aspartic acid and related compounds.

  2007cites this paper